3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Conditions
Glioblastoma
2
Spondylitis, Ankylosing
1
Signs and Symptoms
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Glioma
1
Epilepsy
1
Diarrhea
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Arthritis, Rheumatoid
1
Interventions
Temozolomide
393
Radiotherapy
196
Bevacizumab
156
Radiation
77
Magnetic Resonance Spectroscopy
68
Lomustine
47
Surgical Procedures, Operative
42
Carmustine
41
pembrolizumab
39
Irinotecan
38
Nivolumab
32
Specimen Handling
27
Carboplatin
27
Radiosurgery
24
Erlotinib Hydrochloride
24
Chemotherapy, Adjuvant
23
Radiotherapy, Intensity-Modulated
22
Drug Therapy
21
Cyclophosphamide
20
Aminolevulinic Acid
20
O(6)-benzylguanine
17
sargramostim
16
Radiotherapy, Conformal
15
temsirolimus
14
Granulocyte-Macrophage Colony-Stimulating Factor
14
Everolimus
14
Vorinostat
13
Sorafenib
13
poly ICLC
12
atezolizumab
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Glioblastoma
×
Sulfasalazine
×
Clear all
NCT05664464
2024-05-10
GLUGLIO
University of Zurich
Phase 1/2
Recruiting
120 enrolled
NCT04205357
2023-03-03
SAS-GKRS
Haukeland University Hospital
Phase 1
Completed
24 enrolled